The Clinical Core of the Arizona ADCC is a consortium of six recruitment sites (Banner Alzheimer Institute, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, and the University of Arizona Health Sciences Center and VA medical Center) providing catchment areas throughout the state that function as a standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500 participants at all stages of the aging-dementia spectrum including 325 normal controls, 75 patients with mild cognitive impairment (MCI), and 100 with Alzheimer's disease (AD) and other forms of degenerative dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts. The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data management program, and close working relationships with each of the other Cores. All subjects undergo standardized diagnostic testing that: 1) fulfills strict entrance criteria;2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and genetic measures;3) incorporates the NACC Uniform Data Set (UDS);and 4) employs culturally sensitive test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for and participation in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrollment in the Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). Ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported through other funding mechanisms. These cohorts provide unique opportunities to study the transition between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths in maging, genomics, cognitive neuroscience, and other research methods. To address the goals of the ADCC, subjects and data from independently funded projects are now available as a resource to other researchers, being used in other studies, and will be followed prospectively using the UDS.
The Arizona Alzheimer's Disease Center's Clinical Core includes research participants with or without certain forms of cognitive impairment, who provide DNA and blood samples, have memory and thinking tests each year, and are interested in contributing to their effort, privacy-protected information or biological samples to the scientific understanding, treatment and prevention of Alzheimer's disease. Many of the participants have voluntarily enrolled in a brain donation program, and a number of them are from Arizona's underserved and understudied Latino and Native American communities. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.
|Sabbagh, Marwan N; Shi, Jiong; Lee, Moonhee et al. (2018) Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings. BMC Neurol 18:155|
|Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679|
|Walker, Douglas G; Tang, Tiffany M; Lue, Lih-Fen (2018) Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains. Exp Neurol 309:91-106|
|Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416|
|Wu, Jianfeng; Zhang, Jie; Shi, Jie et al. (2018) HIPPOCAMPUS MORPHOMETRY STUDY ON PATHOLOGY-CONFIRMED ALZHEIMER'S DISEASE PATIENTS WITH SURFACE MULTIVARIATE MORPHOMETRY STATISTICS. Proc IEEE Int Symp Biomed Imaging 2018:1555-1559|
|Cabrera, Erwin; Mathews, Paul; Mezhericher, Emiliya et al. (2018) A? truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis 1864:208-225|
|Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642|
|Tariot, Pierre N; Lopera, Francisco; Langbaum, Jessica B et al. (2018) The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's diseas Alzheimers Dement (N Y) 4:150-160|
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211|
|Beach, Thomas G; Serrano, Geidy E; Kremer, Thomas et al. (2018) Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol 77:793-802|
Showing the most recent 10 out of 794 publications